We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Drug-resistant tuberculosis treatments, the case for a phase III platform trial.
- Authors
Yates, Tom A.; Barnes, Samara; Dedicoat, Martin; Kon, Onn Min; Kunst, Heinke; Lipman, Marc; Millington, Kerry A.; Nunn, Andrew J.; Phillips, Patrick PJ; Potter, Jessica L.; Squireg, S. Bertel
- Abstract
Most phase III trials in drug-resistant tuberculosis have either been underpowered to quantify differences in microbiological endpoints or have taken up to a decade to complete. Composite primary endpoints, dominated by differences in treatment discontinuation and regimen changes, may mask important differences in treatment failure and relapse. Although new regimens for drug-resistant tuberculosis appear very effective, resistance to new drugs is emerging rapidly. There is a need for shorter, safer and more tolerable regimens, including those active against bedaquiline-resistant tuberculosis. Transitioning from multiple regimen A versus regimen B trials to a single large phase III platform trial would accelerate the acquisition of robust estimates of relative efficacy and safety. Further efficiencies could be achieved by adopting modern adaptive platform designs. Collaboration among trialists, affected community representatives, funders and regulators is essential for developing such a phase III platform trial for drug-resistant tuberculosis treatment regimens.
- Subjects
DRUG therapy for tuberculosis; TUBERCULOSIS microbiology; PATIENT safety; CLINICAL trials; DRUG efficacy; TREATMENT failure; DISEASE relapse
- Publication
Bulletin of the World Health Organization, 2024, Vol 102, Issue 9, p657
- ISSN
0042-9686
- Publication type
Article
- DOI
10.2471/BLT.23.290948